




Fig. S1. Synthetic route of the amphiphilic lipopeptide  $C_{18}$ -pArg<sub>8</sub>-pHis<sub>10</sub>




**Fig. S2.** MS spectrum of the C<sub>18</sub>-pArg<sub>8</sub>-pHis<sub>10</sub> lipopeptide



**Fig. S3.**  $^1\text{H-NMR}$  spectrum of the  $C_{18}$ -pArg $_8$ -pHis $_{10}$  lipopeptide



**Fig. S4.** FT-IR resolved map of C<sub>18</sub>-pArg<sub>8</sub>-pHis<sub>10</sub>



|   | RT (min) | Height | Area    | %Area |
|---|----------|--------|---------|-------|
| 1 | 10.900   | 31867  | 30161   | 0.73  |
| 2 | 10.981   | 694557 | 3994294 | 96.63 |
| 3 | 11.083   | 52014  | 109228  | 2.64  |


**Fig. S5.** The purity of the C<sub>18</sub>-pArg<sub>8</sub>-pHis<sub>10</sub> lipopeptide analyzed by HPLC

**Tab. S6.** Effect of different ratio of lipopeptide to PLGA<sub>5k</sub>-PEG<sub>2k</sub> (n = 3)


|                    | EE%<br>(Res) | DL%<br>(Res) | Size<br>(nm) | PDI         | ZP<br>(mV) |
|--------------------|--------------|--------------|--------------|-------------|------------|
| 1: 0<br>(Unstable) | 96.27±0.52   | 2.35±0.05    | 24.58±2.12   | 0.306±0.162 | 24.8±2.7   |
| 2: 1<br>(Clear)    | 98.34±0.63   | 6.45±0.11    | 93.47±1.23   | 0.308±0.120 | 14.3±1.2   |
| 1: 1<br>(Clear)    | 99.48±1.26   | 8.24±0.21    | 103.52±2.31  | 0.144±0.072 | 7.6±0.9    |
| 1: 2<br>(Clear)    | 99.36±1.87   | 9.05±0.17    | 126.48±2.56  | 0.099±0.095 | -3.7±0.2   |
| 0: 1<br>(Clear)    | 99.54±1.62   | 9.56±0.18    | 114.21±1.11  | 0.056±0.057 | -13.9±1.5  |

**Tab. S7.** Characterization of different preparations (N/P = 15)


| Preparations | Size (nm) | PDI       | ZP (mV)   | EE (%)<br>(Res) | EE (%)<br>(siP) | DL (%)<br>(Res) | DL (%)<br>(siP) |
|--------------|-----------|-----------|-----------|-----------------|-----------------|-----------------|-----------------|
| Blank SLNP   | 105.4±1.7 | 0.14±0.02 | 7.68±0.74 | —               | —               | —               | —               |
| Res@SLNP     | 113.6±1.6 | 0.10±0.01 | 6.23±1.12 | 99.56±1.47      | —               | 8.37±0.24       | —               |
| Res/siP@SLNP | 127.9±1.8 | 0.12±0.02 | 0.90±0.06 | 99.23±1.13      | 92.19±1.01      | 7.93±0.19       | 2.53±0.05       |




**Fig. S8. Indicators of immunity in the immunosuppressed mouse model.** (A) The counts of peripheral blood cells (leukocytes, lymphocytes, hemoglobin and platelets) (n=5) (B) Changes in body weight of mice (n=5) (C) immune organ index in the immunosuppressed group and the normal group (n=5). Dates are shown as mean $\pm$ SD, n.s.: not significant, \*\*p < 0.01, \*\*\*p < 0.001.




**Fig. S9. The percentages of T cells and B cells in the peripheral blood of immunosuppressed mice during the experiment. (A) Representative contour plot and (B) statistical analysis of T cells percentage gated on white blood cells. (C) Representative contour plot and (D) statistical analysis of B cells percentage gated on white blood cells. Dates are shown as mean  $\pm$  SD, \*\*\* $p < 0.001$ .**



**Fig. S10.** Changes in mice body weight during treatment in the immunosuppressed model (n = 5).




**Fig. S11.** Raw wb data for Fig.2c.




**Fig. S12.** Raw wb data for Fig.2h.

Fig.6b




**Fig. S13.** Raw wb data for Fig.6b.


Fig.6d




**Fig. S14.** Raw wb data for Fig.6d.



**Fig. S15.** Raw electrophoresis image for Fig.1c.



**Fig. S16.** Raw electrophoresis image for Fig.1d.



**Fig. S17.** Raw electrophoresis image for Fig.1e.